Serum miR-210 Contributes to Tumor Detection, Stage Prediction and Dynamic Surveillance in Patients with Bladder Cancer

Yongmei Yang; Ailin Qu; Jingkang Liu; Rui Wang; Yingjie Liu; Gang Li; Weili Duan; Qian Fang; Xiumei Jiang; Lili Wang; Guixi Zheng; Lutao Du; Xin Zhang; Chuanxin Wang

doi:10.1371/journal.pone.0135168

Serum miR-210 Contributes to Tumor Detection, Stage Prediction and Dynamic Surveillance in Patients with Bladder Cancer

PLoS One. 2015 Aug 7;10(8):e0135168. doi: 10.1371/journal.pone.0135168. eCollection 2015.

Authors

Yongmei Yang¹, Ailin Qu¹, Jingkang Liu¹, Rui Wang¹, Yingjie Liu¹, Gang Li², Weili Duan¹, Qian Fang¹, Xiumei Jiang¹, Lili Wang¹, Guixi Zheng¹, Lutao Du¹, Xin Zhang¹, Chuanxin Wang¹

Affiliations

¹ Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong Province, China.
² Department of Urology, Honggang Hospital, Dongying, Shandong Province, China.

Abstract

MiR-210 is the master hypoxamir that generally exhibits oncogenic properties in most human solid tumors including bladder cancer (BC). However, it remains unknown about the clinical significance of circulating miR-210 levels in BC. In this study, we found that serum miR-210 was up-regulated in patients with BC, and serum levels of miR-210 increased with advancing stage and grade. Moreover, serum miR-210 expression was found to be significantly reduced in paired post-operative samples and elevated in most patients with relapsed BC. Taken together, our data suggest that serum miR-210 could be a potential noninvasive biomarker for screening, predicting and monitoring BC.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Biomarkers, Tumor / blood
Case-Control Studies
Cell Line, Tumor
DNA, Complementary / metabolism
Female
Gene Expression Regulation, Neoplastic*
Humans
Male
MicroRNAs / blood*
MicroRNAs / genetics*
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Retrospective Studies
Up-Regulation
Urinary Bladder Neoplasms / blood*
Urinary Bladder Neoplasms / genetics*

Substances

Biomarkers, Tumor
DNA, Complementary
MIRN210 microRNA, human
MicroRNAs

Grants and funding

This study was supported by National Natural Science Foundation of China (No. 81271916); Shandong Province Natural Science Foundation of China (Nos. ZR2010H004, ZR2013HQ063 and ZR2014HP001); Fundamental Research Funds of Shandong University (No. 2014QLKY03); Research Fund for the Doctoral Program of Higher Education of China (No. 20120131110055) and National Key Clinical Medical Specialties Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.